Proteasomal inhibition after injury prevents fibrosis by modulating TGF-β1signalling
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The development of organ fibrosis after injury requires activation of transforming growth factor β(1) which regulates the transcription of profibrotic genes. The systemic administration of a proteasomal inhibitor has been reported to prevent the development of fibrosis in the liver, kidney and bone marrow. It is hypothesised that proteasomal inhibition would prevent lung and skin fibrosis after injury by inhibiting TGF-β(1)-mediated transcription. METHODS: Bortezomib, a small molecule proteasome inhibitor in widespread clinical use, was administered to mice beginning 7 days after the intratracheal or intradermal administration of bleomycin and lung and skin fibrosis was measured after 21 or 40 days, respectively. To examine the mechanism of this protection, bortezomib was administered to primary normal lung fibroblasts and primary lung and skin fibroblasts obtained from patients with idiopathic pulmonary fibrosis and scleroderma, respectively. RESULTS: Bortezomib promoted normal repair and prevented lung and skin fibrosis when administered beginning 7 days after the initiation of bleomycin. In primary human lung fibroblasts from normal individuals and patients with idiopathic pulmonary fibrosis and in skin fibroblasts from a patient with scleroderma, bortezomib inhibited TGF-β(1)-mediated target gene expression by inhibiting transcription induced by activated Smads. An increase in the abundance and activity of the nuclear hormone receptor PPARγ, a repressor of Smad-mediated transcription, contributed to this response. CONCLUSIONS: Proteasomal inhibition prevents lung and skin fibrosis after injury in part by increasing the abundance and activity of PPARγ. Proteasomal inhibition may offer a novel therapeutic alternative in patients with dysregulated tissue repair and fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments
Bustin, S. A., Benes, V., Garson, J. A., Hellemans, J., Huggett, J., Kubista, M., Mueller, R., Nolan, T., Pfaffl, M. W., Shipley, G. L., et al. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.112797 · Cited by 16,303
Cellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
Fat and Beyond: The Diverse Biology of PPARγ
Tontonoz, P., & Spiegelman, B. M. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.061307.091829 · Cited by 2,085
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients
Bringhen, S., Larocca, A., Rossi, D., Cavalli, M., Genuardi, M., Ria, R., Gentili, S., Patriarca, F., Nozzoli, C., Levi, A., et al. (2010) · Blood · doi:10.1182/blood-2010-07-294983 · Cited by 381 · cited 1×
“This finding is similar to the results obtained in clinical trials using a weekly dosing schedule for the treatment of haematological malignancies.(28) It has been speculated that differential clearance of bortezomib from the serum and tissues explains the discrepancy between the kinetics of recovery of proteasomal ac…”
ResultImatinib Treatment for Idiopathic Pulmonary Fibrosis: Randomized Placebo-controlled Trial Results
Daniels, C. E., Lasky, J. A., Limper, A. H., Mieras, K., Gabor, E., & Schroeder, D. R. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200906-0964oc · Cited by 373 · cited 1×
“A recent clinical trial of imatinib in patients with idiopathic pulmonary fibrosis failed to show improvement in mortality or in lung physiological parameters.(38) Based on these and other data, some investigators have advocated that only drugs that are effective in preventing fibrosis when administered after bleomyci…”
BackgroundGhosh, A. K., Bhattacharyya, S., Lakos, G., Chen, S., Mori, Y., & Varga, J. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20104 · Cited by 201
Self-citationWu, M., Melichian, D. S., de la Garza, M., Gruner, K., Bhattacharyya, S., Barr, L., Nair, A., Shahrara, S., Sporn, P. H. S., Mustoe, T. A., et al. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.090241 · Cited by 125
Self-citation
Cited by
Pathogenesis of Systemic Sclerosis
Pattanaik, D., Brown, M., Postlethwaite, B. C., & Postlethwaite, A. E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00272 · Cited by 405
Meiners, S., Eickelberg, O., & Königshoff, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00186914 · Cited by 340
The Role of Myofibroblasts in Physiological and Pathological Tissue Repair
Schuster, R., Younesi, F., Ezzo, M., & Hinz, B. (2023) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a041231 · Cited by 232
Transforming Growth Factor (TGF)-β Promotes de Novo Serine Synthesis for Collagen Production
Nigdelioglu, R., Hamanaka, R. B., Meliton, A. Y., O'Leary, E., Witt, L. J., Cho, T., Sun, K., Bonham, C., Wu, D., Woods, P. S., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.756247 · Cited by 169
Self-citationThe effects of miR-27a-3p-mediated Smurf2 on bleomycin A5-induced pulmonary fibrosis in rats
Zhang, J., Zhang, J., & Zhang, Q. (2020) · Cellular and Molecular Biology · doi:10.14715/cmb/2020.66.3.12 · Cited by 5
Metadata
- Authors
- Mutlu, G. M., Budinger, G. R. S., Wu, M., Lam, A. P., Zirk, A., Rivera, S., Urich, D., Chiarella, S. E., Go, L. H. T., Ghosh, A. K., Selman, M., Pardo, A., Varga, J., Kamp, D. W., Chandel, N. S., Sznajder, J. I., & Jain, M.
- Venue
- Thorax
- Publisher
- BMJ
- Published
- 2011-09-15
- Volume
- 67
- Issue
- 2
- Pages
- 139-146
- ISSN
- 0040-6376 (ISSN-L)
- 1468-3296
- OpenAlex
- W2141645006
- Cited by
- 81
- References
- 7
- FWCI
- 5.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Proteasomal inhibition after injury prevents fibrosis by modulating TGF-β1signalling. https://app.cochat.ai/papers/10.1136/thoraxjnl-2011-200717
- The paper
- Mutlu, G. M., Budinger, G. R. S., Wu, M., Lam, A. P., Zirk, A., Rivera, S., Urich, D., Chiarella, S. E., Go, L. H. T., Ghosh, A. K., Selman, M., Pardo, A., Varga, J., Kamp, D. W., Chandel, N. S., Sznajder, J. I., & Jain, M. (2012). Proteasomal inhibition after injury prevents fibrosis by modulating TGF-β1signalling. Thorax. https://doi.org/10.1136/thoraxjnl-2011-200717
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.